Tezspire™ (tezepelumab)

I. Medication Description
Tezspire™ is a thymic stromal lymphopoietin (TSLP) blocker, human monoclonal antibody (IgGλ) indicated for add-on maintenance treatment of adult and pediatric patients aged 12 and older with severe asthma.

II. Position Statement
Coverage is determined through a prior authorization process that must include supporting clinical documentation for each request.

III. Initial Coverage Criteria
Member must meet all the following criteria:
- Must be 12 years of age or older
- Has diagnosis of severe asthma
- Must be prescribed by or in consult with an appropriate specialist (allergist, pulmonologist, immunologist)
- Has a history of severe asthma attacks despite treatment with inhaled corticosteroid (ICS) in combination with long-acting beta₂-agonist (LABA) inhaler at optimized doses for three consecutive months
- Will continue to use ICS in combination with LABA inhaler at optimized dose
- Provider attests member will not use Tezspire® concomitantly with other biologics.

IV. Renewal Coverage Criteria
Member must meet all the following criteria:
- Has been adherent to Tezspire™ and ICS/LABA therapy
- Has experienced a positive clinical response (reduction in frequency and/or severity of symptoms and exacerbations or medication dose reduction)
- Annual specialist consult provided if prescriber not a specialist.

V. Quantity Limitations
Max 210mg SQ every 4 weeks

VI. Coverage Duration
Initial approval duration: 1 year
Renewal approval duration: 1 year